Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
A RANDOMIZED, PARTIALLY-BLIND, PLACEBO-CONTROLLED, PILOT, DOSE-RANGING STUDY TO ASSESS THE EFFECT OF GWP42003 ON LIVER FAT LEVELS IN SUBJECT WITH FATTY LIVER DISEASE GW Rejected Cannabidiol 2a GWZMD1188 KKUH
A Phase III, Multicenter, Randomized, Open-Lable Clinical Trial Comparing the Efficacy and Safety of MK-0431 A (the Fixed-Dose Combination of Sitagliptin and Metformin) to That of Liraglutide in Patients With Type 2 Diabetes Mellitus MSD Terminated MK-0431A (Sitagliptin / Metformin) vs Liraglutide 3 MK-0431A-180-00 KKUH
A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study) AstraZeneca Ongoing Ticagrelor 3b D513BC00001 King Khalid University Hospital (Riyadh)
An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment Boehringer Ingelheim Completed BIBW 2992+ Vinorelbine VS.Trastuzumab 3 1200.75 KFMC
A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer Novartis Ongoing LEE011 (Ribociclib) 3 CLEE011E2301 KKUH
A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents Sanofi Ongoing HOE901 (insulin glargine)/ AVE0010 (lixisenatide) combination IIIb LPS15017 KFMC
Use of high dose of Colistin in Multidrug Resistant Gram Negative infections. Randomized Controlled clinical Trial King Saud Medical City Completed Colistin 4 KSMC-12-13 King Saud Medical City
"easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment" Merck Serono Rejected - 4 200104-534 King Khalid University Hospital (Riyadh)
"AN OBSERVATIONAL, NON-INTERVENTIONAL,MULTI-CENTER, MULTI-NATIONAL STUDY OFPATIENTS WITH ATYPICAL HEMOLYTIC-UREMICSYNDROME(AHUS REGISTRY)" Alexion Rejected - 4 M11-001 N/A
A Phase IV Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 month consumption of Vetal Laban Including Lactobacillus acidophilus NCFM on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for A Phase IV, Randomized, double-blind, placebo-controlled study with parallel groups Irritable Bowel Syndrome Almarai Rejected Vetal Laban containing Lactobacillus acidophilus NCFM at 1.6 x 109 CFU per container 4 IBS - 0920 King Fahad Medical City (Riyadh)
View 351 - 360 From 701